Carrier Screening for Genetic Conditions


Prenatal genetic carrier screening has evolved over a period of about 25 years. Advances in technology and health policy have ushered this evolution. With these changes, new terminology has appeared, whereas old terms and their definitions have evolved. It is helpful for the reader to understand the current core terminology around the topic of carrier screening.


Condition : There has been a general trend to replace the term “disease” with “condition.” Genetic testing and screening, when applied to populations of healthy people, will commonly uncover health risk to either themselves or their offspring. This can provoke unnecessary anxiety. Furthermore, there is less stigmatization associated with “condition” compared with “disease.”

Primary prevention: A public health strategy aimed at preventing or minimizing the impact on health, such as vaccination in preventing infectious diseases. Prenatal genetic carrier screening can play a role in primary prevention when at risk couples use assisted reproductive technologies (ARTs) in their reproductive planning.

Secondary prevention : A public health strategy aimed at identifying and limiting early disease. Papanicolaou screening for cervical cancer is an example. Carrier genetic screening can play a role in secondary prevention. Postconception decision-making falls into this category of secondary prevention.

Mutation : When referring to changes in the sequence of a gene, this term has generally been replaced by “variant.” Variant has less stigmatization and is less definitive, allowing for classification according to its relationship with a condition of interest (e.g., benign, pathogenic).

Pathogenic variant ( i.e., PV) : A category assigned to variants in a gene that are associated with a condition. The caution here is that penetrance may not be 100%, and there may be variable expressivity (see below).

Likely pathogenic variant : A category assigned to pathogenic variants in a gene where the association with a condition is less certain.

Benign variant : A category assigned to variants in a gene that are clearly not associated with a condition.

Likely benign variant : A category assigned to variants in a gene that are most likely not associated with a condition, but where the benign nature is less certain.

Variant of uncertain significance ( i.e., VUS) : A category of variants in a gene where the variant cannot be placed into either of the above four categories. These variants are numerous and are often the most challenging for clinicians, as they bring uncertainty into management and treatment decisions.

Residual risk : The risk that remains after a negative screening test result. Applied to genetic carrier screening, residual risk is conceptualized by the following formula:

Carrier frequency of a condition × (1 − detection rate)

Next-generation sequencing (NGS) : Generally applied to sequencing technologies that allow simultaneous sequence multiple distinct regions of the genome. It is considerably faster and cheaper than traditional Sanger sequencing.

Whole-genome sequencing (WGS): (Now referred to as genome-sequencing by the American College of Medical Genetics and Genomics (ACMG)) Sequencing the entire genome of an individual. This requires NGS.

Whole-exome sequencing (WES): (Now referred to as exome-sequencing by ACMG) Sequencing that selectively targets the protein-coding regions of the genome. Most known pathogenic variants are in these protein-coding regions; therefore, selectively sequencing these regions can reduce cost relative to WGS.

Genotyping: A technological method of assaying genetic variants that targets known pathogenic variants. This approach is faster and less expensive compared with NGS. It allows for simultaneous assay of up to hundreds of thousands of variants. Variants that are not part of the prespecified genotyping platform will not be assayed.

Pan-ethnic screening : This is an approach to carrier screening where all ethnic groups are screened the same way. For example, if pan-ethnic screening for sickle cell disease is the goal, then it is not only performed among individuals of African descent but also applied to all ethnic groups in the same fashion.

Expressivity : Expressivity reflects how a genetic variant can manifest phenotypically. It recognizes that a pathogenic variant can be associated with a range of phenotypes (i.e., variable expressivity). For example, a variant causing Alagille syndrome may present with hepatic dysfunction in some individuals, but not in others.

Penetrance : The percentage of people with a pathogenic variant who develop the associated phenotype. Population-based genotyping has uncovered that many pathogenic alleles are not highly penetrant. Incomplete penetrance makes selecting variants for testing on a carrier screening panel challenging. Incomplete penetrance also challenges interpretation of screening results and downstream clinical decision-making.

What are the principles of genetic screening?

Traditionally, carrier screening, as recognized by Wilson and Jungner, was a form of secondary prevention. Its application was largely in public health in the same realm as infectious diseases (e.g., tuberculosis [TB], syphilis). In public health, screening tests are applied to populations broadly (e.g., testing children before enrollment into school) or in a more targeted fashion based on known risk factors (e.g., prisoners). Historically, screening tests were inexpensive and noninvasive. They are generally low technology or amenable to automation, which allows high throughput. Examples include the rapid plasma reagin blood test (RPR) for syphilis or the Mantoux skin test for TB. Because screening tests have an associated false-positive rate, they are often followed with confirmatory diagnostic testing before treatments begin. Diagnostic tests generally have lower false-positive and false-negative rates but can be more expensive and/or more invasive.

Prenatal genetic carrier screening is distinct from primary or secondary prevention screening in several ways that contrast with those described by Wilson and Jungner for traditional screening tests and are important for the clinician to appreciate ( Table 7.1 ):

  • 1.

    Targets a broad population (like primary prevention screening).

  • 2.

    It is noninvasive (like primary prevention screening).

  • 3.

    The same test/method can be used for screening and diagnosis in that there may be no follow-up diagnostic test available or required.

  • 4.

    It is generally expensive (like a diagnostic test).

  • 5.

    Excluding VUS, the false-positive rate is low (like a diagnostic test).

  • 6.

    There is almost always a false-negative rate (e.g., residual risk).

  • 7.

    Screening generally has health implications for the offspring and not the person being screened (some exceptions apply).


Wilson and Yunger Characteristics of Screening Tests

Conditions Screened Condition with a personal/societal burden
Well known natural history
Detectable at an early stage
Early stage treatment beneficial
Test Characteristics Suitable for early stage detection
Acceptable by patients
Repeat testing intervals determined
Social Health care supervision is adequate for increased work burden
Physical and psychologic benefits are greater than risks of screening
Costs and benefits are balanced

Unlike most screening examinations and laboratory tests in which there is a high detection rate and low specificity, prenatal genetic carrier screening generally has high detection rate (DR) for the variants being examined. However, because all variants may not be tested or reported, the false-negative rate can be quite high. This has the potential to yield a low negative predictive value (NPV) compared with what is seen with traditional primary screening, but the low prevalence of specific conditions screened tempers this potential. Residual risk is a surrogate for NPV in clinical genetics practice where carrier screening is the focus. The key components of residual risk are carrier frequency within the population of interest and the screening test DR. There is a residual risk for nearly every condition screened.

These characteristics that distinguish prenatal genetic carrier screening from traditional screening modalities make it a unique entity in public health. These distinguishing features equate to unique challenges around policy, education of patients and providers, as well as implementation.

What is expanded carrier screening?

Unlike screening for one condition at a time (i.e., a la carte testing), expanded carrier screening (ECS) adds breadth (more conditions) and depth (interrogation of or reporting on more variants within a gene). It has a reduced false-negative rate for specific genes (because of the increased number of variants examined) and higher sensitivity for detecting carriers across a broad spectrum of conditions.

Carrier screening has three dimensions: (1) population(s) screened, (2) gene(s) interrogated, and (3) variant(s) classified. A Rubik cube model illustrates the three axes involved ( Fig. 7.1 ). When prenatal genetic screening first began, small groups of people were the focus (the bottom left cube with red stripes). These small groups included families with an affected proband for a condition or an ethnic group at risk for certain genetic conditions such as individuals of Ashkenazi Jewish descent. Specific conditions were the focus, and a limited number of genetic variants were probed for. With enhanced sequencing technology that included higher throughput, there was an expansion to targeting subpopulations and the number of variants categorized grew. There was no longer an ethnic-based focus on conditions, and screening became less restricted to conditions observed in the family. Over time, screening has allowed for a pan-ethnic paradigm for some conditions.

FIG. 7.1

The Rubik’s Cube has three axes. The horizontal axis represents population screened. The vertical axis represents variants classified, and the diagonal axis represents the genes interrogated. Each of the 18 cubes corresponds to a combination of points along each axis. Screening has its origin in the red striped cube (foreground bottom left) and is progressing rapidly to the green checkered cube (background top right).

Modified from Gregg AR. Expanded carrier screening. Obstet Gynecol Clin N Am . 2018;45:103–112.

How does prenatal screening utilize the structure of the human genome?

The human genome comprises approximately 3 billion nucleotides (or letters; A’s, C’s, G’s, and T’s) that serve as the blueprint for all of life. The DNA sequence comprised of these nucleotides, which can be thought of as a string of combinations of the above-mentioned letters/nucleotides, encode for all of the proteins that become part of cells, tissues, and organs. These 3 billion nucleotides are separated into 23 different chromosomes, which are densely packaged segments of DNA. The DNA sequence codes for approximately 20,000 different genes, which are the functional unit of the genome; in general, each gene encodes for a single protein. For example, the CFTR gene encodes for the cystic fibrosis transmembrane conductance regulator protein, a transporter protein that helps transport chloride in and out of cells. However, the fraction of DNA that codes for genes only comprises a small proportion (approximately 1.5%) of the whole genome. Interspersed between the gene “coding” sequences are long stretches of DNA that are “noncoding.” These noncoding regions of the genome have critical regulatory roles in that they determine which genes are turned on in a given cell type or condition. By turning on different genes in different cell types, each cell type can have a specific form and function.

The sequence of everyone’s genome is largely the same. However, the DNA sequence differs at approximately 1 in 1000 nucleotides between any two individuals. These differences in the DNA sequence are called genetic variants. All genetic variants originally arise in a single individual as a mutational event, where the sequence of the genome is copied incorrectly when DNA is passed from one generation to the next. These variants can have a wide range of downstream effects. If the variant occurs in a noncoding region of the genome, it may affect the gene regulatory potential of that DNA sequence, or it may have no effect at all. Similarly, if the variant occurs in a region of the genome that codes for a gene, it may have no effect at all on the resultant protein product, or it may have tremendous deleterious effects on its function, or in some cases even improve the function of that encoded protein.

Genetic variation comes in many forms. The simplest and most common form of variation is single nucleotide polymorphisms, or SNPs, which are single nucleotide changes in the genome. Next are indels, which are short insertions or deletions of several nucleotides in the genome. Lastly, copy number variants (CNVs) and structural variants (SVs) are large structural changes of much greater size (hundreds of nucleotides or more).

The fundamental challenge of diagnostic and prenatal screening is identifying which variants in a gene can cause genetic conditions. Most of the genetic variants in the population are common and thus shared by many individuals in the population. Furthermore, most variants are benign, with no apparent effect on downstream protein function or known condition. Each gene contains many different variants, which have a wide range of effects. There have been considerable coordinated efforts such as ClinGen to distinguish which variants are benign versus pathogenic for disease. It should be noted that the clear majority of variants in a given gene are not pathogenic.

What technologies are used to screen for genetic conditions?

To screen for genetic variants capable of causing disease, we need to be able to read the DNA sequence of an individual and compare it with a reference sequence. Over the years, the technology used to sequence DNA has changed rapidly and with it has changed how we perform gene screening.

The oldest method of DNA sequencing is Sanger sequencing. Despite still being the most accurate form of sequencing, this method has very low throughput and is expensive and generally manually intensive. In a given sequencing reaction, only a short segment of DNA (generally less than 1000 nucleotides) can be interrogated. However, given its accuracy, it is still used as confirmation for findings from other sequencing technologies as described below.

Over the past decade, the advent of next-generation sequencing (NGS) has transformed our ability to screen and diagnose genetic conditions. NGS refers to high-throughput sequencing methods, which allow for simultaneous sequencing of multiple distinct regions of the genome (i.e., parallelization), which contrasts with traditional Sanger sequencing. NGS technologies generate sequencing “reads,” which are simply readouts (As, Ts, Cs, and Gs) of the sequence of a segment of an individual’s DNA. Once the sequence of each read is determined, the reads can be mapped to a reference genome sequence, and computational methods can be applied to identify differences from the reference genome (i.e., genetic variants). NGS can allow for sequencing of the entire genome (i.e., WGS) or a select panel of regions of the genome such as the set of all protein-coding genes (i.e., WES).

A separate technology that is commonly used is genotyping. In contrast to NGS or Sanger sequencing where entire stretches of DNA are read, genotyping assays just one nucleotide at a time. A genotyping reaction thus allows us to determine the genotype at prespecified variant sites but does not allow us to uncover variants that are not part of the designed genotyping assay. However, genotyping is much cheaper, and with higher throughput than NGS or Sanger sequencing—in one genotyping reaction, hundreds of thousands of variants can be assayed. It is particularly applicable when there are known genetic variants that have a large disease burden, such as the sickle cell mutation, allowing for rapid and high-throughput screening of that variant in many individuals.

It should be noted that prenatal genetic carrier screening panels can use any of the three above technologies. Furthermore, a single panel may use multiple different modalities, with different technologies used for different genes/variants because of technical considerations.

What Is the Goal of Prenatal Genetic Carrier Screening?

Prenatal genetic carrier screening identifies individuals and couples at risk of transmitting genetic variants to their offspring at the time of fertilization. The genetic variants that are of interest in the context of prenatal genetic screening are those that can result in undesired developmental abnormalities and/or function. Birth defects and developmental delay are examples of conditions for which it may be desirable to screen.

The major goal of prenatal genetic screening is to provide desired information to individuals or couples. The information gained from carrier screening can be used in reproductive decision-making. The clinical utility of screening is related to the time it takes to make screening results available to couples.

Identification of at-risk couples ideally takes place during the preconception period, but the reality is that screening most often occurs once a pregnancy is established. In some ethnic communities, knowledge of carrier status can even impact whether a couple decides to marry (such as Ashkenazi Jewish communities). Knowledge of carrier status before conception may impact the reproductive choices a couple makes. For example, a couple where each partner carries a pathogenic variant in CFTR may decide not to conceive because of concern of having a child with cystic fibrosis. Knowledge of a couple’s carrier status may also impact the decision to use donor games (i.e., sperm or egg) or to opt for preimplantation genetic diagnosis. However, as described below, knowledge of carrier status before conception can also impact the other benefits of carrier screening.

When prenatal genetic carrier screening occurs after conception, it can impact decision-making. This includes whether to proceed with diagnostic testing (e.g., chorionic villous sampling or amniocentesis), perinatal management, and/or discontinuing a pregnancy. Knowledge that both parents are carriers of recessive pathogenic variants for a given condition greatly increases the likelihood of having a child who is affected. In this scenario, diagnostic testing would provide the opportunity to ascertain whether a fetus did in fact receive both pathogenic variants from the parents. For some conditions, it may also influence the management provided in the perinatal period. For example, the diagnosis of a genetic condition associated with congenital cardiac defects may spur additional screening for cardiac anomalies and preparation at delivery with the appropriate medical personnel (e.g., delivering at a medical center with extensive expertise in high-risk obstetrics, cardiac surgery, and neonatology). Furthermore, when results are delivered after conception but early in pregnancy, couples can learn about the care of a child/adult with conditions for which they are at risk, and with this information determine whether they will continue to carry a pregnancy. In summary , carrier screening aims to provide couples information about their risk of conceiving or carrying a child with a genetic condition characterized by Mendelian inheritance.

What Factors Determine the Appropriateness of Screening for a Gene or Condition?

For the most part, prenatal genetic carrier screening applies to recessive conditions, where a pathogenic variant within a gene transmitted from each parent would result in a defined genetic condition. In this scenario, the parents are unaffected. Carrier screening is less applicable in dominant conditions because the parent transmitting the pathogenic variant would also be affected with the condition, assuming full penetrance. Genes that are more suitable for screening also tend to have genetic variants that are highly penetrant, as interpretation of low-penetrant variants can be very challenging. Most genes suitable for screening are reliably sequenced. However, there are exceptions. Genes responsible for fragile X mental retardation syndrome (FMR), spinal muscular atrophy (SMA), and congenital adrenal hyperplasia (CAH) offer special challenges. They require special methods to determine carrier status because of the repetitive nature of the variant (trinucleotide repeats in FMR) or the presence of pseudogenes in the same region (CAH and SMA). The added complexity in screening these genes does not disqualify them for screening, although these genes require special attention during the screening process.

Following the tenets of Wilson and Jungner, the genes screened should be associated with severe conditions. However, determining which conditions are “severe” is a challenging task. One study surveyed a large group of healthcare professionals and found that consensus can be reached when stratifying severity of specific conditions. The study found that conditions associated with intellectual disability and reduction in life span during infancy, childhood, or adolescence were found to be the characteristics that led to high severity ratings. Defining the severity of conditions is further complicated by the wide phenotypic spectrum of some conditions and the different values that patients place on the clinical features of some conditions. Furthermore, our ability to treat some conditions is changing rapidly such that some conditions viewed as “severe” in the past may now be treated and lead to a new perception of severity for that condition. Counseling after the return of results in prenatal carrier screening should remain sensitive to varied perceptions of severity.

In summary , there is general agreement that the conditions appropriate for screening are actionable. This term has broad connotation and encompasses medical interventions and patient values.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jan 5, 2020 | Posted by in PEDIATRICS | Comments Off on Carrier Screening for Genetic Conditions

Full access? Get Clinical Tree

Get Clinical Tree app for offline access